oxygen deprivation during sleep. Its lead investigational candidate, AD109, is a fixed-dose combination of aroxybutynin and atomoxetine being evaluated in Phase 3 trials as a bedtime pill for adults with mild, moderate, and severe obstructive sleep apnea who are untreated or undertreated. Apnimed also advances additional oral candidates such as AD504 and AD182, as well as other programs through a joint venture with Shionogi & Co., Ltd. The company’s work includes clinical research, real-world evidence studies, and community-focused initiatives to better characterize disease burden and unmet medical needs in sleep-related breathing disorders.